Skip to main content
Caplight Logo









Auransa

Auransa

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.auransa.com/

Last Round

VC Round

Jan 3, 2019

Est. Valuation

$70.37M

Total Funding Raised

$16.95M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Auransa is a biotechnology company that has developed an AI-driven platform to discover and develop precision medicines for cancer.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

drug discoveryprecision medicineAI drug discoveryin silico drug discoverymulti-omicspatient stratificationbiomarker discoverycomputational biologytherapeutic target identificationbiopharmasmall-molecule drugclinical trial optimizationdrug development pipelineAI-native biotechoncology research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Auransa Comparables

Compare Auransa with similar companies based on industry and business-model similarity.

Auransa comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VeriSIM Life
83%
Healx
82%
Aitia
81%

Auransa Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 3, 2019
Series AMay 31, 2017
SeedDec 22, 2014

Key People

Founding team and executive leadership

Pek Lum

Founder And CEO

Founding Team

Auransa Investors

Notable investors and investment history

Auransa investors
InvestorRounds
Lux CapitalSeed, Series A, VC Round
AME Cloud VenturesSeed, Series A, VC Round
11.2 CapitalSeed, Series A, VC Round
DCVC (Data Collective)Seed, Series A, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors grew 399% MoM, from 287 to 1.4K.

  • May 31, 2017

    $14.1M round led by Lux Capital and DCVC.

Auransa Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Auransa Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Auransa's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range11
Year Founded2014
Last FundingJan 3, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?